Upgrade to SI Premium - Free Trial

Travere Therapeutics (TVTX)

56.26 -0.32 (0.57%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 10, 2026 5:00 PM - BizWire Form 8-K Travere Therapeutics, For: Jul 06 July 9, 2026 5:10 PM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim June 25, 2026 7:38 AM - StreetInsider Form 4 Travere Therapeutics, For: Jun 22 Filed by: Inrig Jula June 22, 2026 4:37 PM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $61 at Wedbush June 22, 2026 8:09 AM - StreetInsider Form S-8 Travere Therapeutics, June 17, 2026 4:33 PM - SEC Filing Form 4 Travere Therapeutics, For: Jun 12 Filed by: Coughlin Timothy June 16, 2026 4:47 PM - SEC Filing Form 4 Travere Therapeutics, For: Jun 12 Filed by: Baynes Roy D. June 16, 2026 4:43 PM - SEC Filing Form 8-K Travere Therapeutics, For: Jun 12 June 16, 2026 4:35 PM - SEC Filing Travere Therapeutics names new R&D head ahead of 2027 retirement June 16, 2026 4:30 PM - StreetInsider Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 June 16, 2026 4:30 PM - BizWire Travere Therapeutics (TVTX) PT Raised to $70 at Citi June 15, 2026 5:35 AM - StreetInsider Form 144 Travere Therapeutics, Filed by: Baynes Roy D. June 12, 2026 4:05 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Coughlin Timothy June 12, 2026 12:20 PM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $65 at Wells Fargo June 12, 2026 6:33 AM - StreetInsider Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 11, 2026 5:00 PM - BizWire Travere presents long-term FILSPARI data at European kidney conference June 4, 2026 10:09 AM - StreetInsider Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress June 4, 2026 10:09 AM - BizWire Travere Therapeutics (TVTX) PT Raised to $62 at Citi June 3, 2026 12:53 PM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $67 at H.C. Wainwright June 2, 2026 11:38 AM - StreetInsider Form 8-K Travere Therapeutics, For: Jun 01 June 2, 2026 7:05 AM - SEC Filing Travere licenses BTK inhibitor from Everest for rare kidney diseases June 2, 2026 7:01 AM - StreetInsider Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases June 2, 2026 7:01 AM - BizWire Travere receives patent allowance for FILSPARI use in kidney disease May 27, 2026 4:05 PM - StreetInsider Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy May 27, 2026 4:05 PM - BizWire Form 4 Travere Therapeutics, For: May 19 Filed by: Williams Brinkley Ruth May 21, 2026 5:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Orwin John A May 21, 2026 5:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Meckler Jeffrey A May 21, 2026 5:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Poole Sandra May 21, 2026 5:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Squarer Ron May 21, 2026 5:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Bruhn Suzanne Louise May 21, 2026 5:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: LYONS GARY A May 21, 2026 5:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Baynes Roy D. May 21, 2026 5:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Coughlin Timothy May 21, 2026 5:00 PM - SEC Filing Form 8-K Travere Therapeutics, For: May 19 May 21, 2026 4:08 PM - SEC Filing Form 4 Travere Therapeutics, For: May 15 Filed by: Coughlin Timothy May 19, 2026 4:05 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Coughlin Timothy May 15, 2026 12:51 PM - SEC Filing Form SCHEDULE 13G Travere Therapeutics, Filed by: ARMISTICE CAPITAL, LLC May 15, 2026 11:17 AM - SEC Filing Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 12, 2026 5:00 PM - BizWire Form 8-K Travere Therapeutics, For: May 06 May 11, 2026 5:10 PM - SEC Filing Travere Therapeutics to Participate at Upcoming Investor Conferences May 7, 2026 4:30 PM - BizWire Form 424B5 Travere Therapeutics, May 7, 2026 4:19 PM - SEC Filing Form 305B2 Travere Therapeutics, May 7, 2026 4:02 PM - SEC Filing Form FWP Travere Therapeutics, Filed by: Travere Therapeutics, Inc. May 7, 2026 6:08 AM - SEC Filing Travere prices $475 million convertible notes to refinance 2029 debt May 6, 2026 10:28 PM - StreetInsider Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes May 6, 2026 10:28 PM - BizWire Form 4 Travere Therapeutics, For: May 05 Filed by: Baynes Roy D. May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: REED ELIZABETH E May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: ROTE WILLIAM E. May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: Meckler Jeffrey A May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: Heerma Peter May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: Inrig Jula May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: Cline Christopher R. May 6, 2026 8:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: Dube Eric M May 6, 2026 8:00 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Cline Christopher R. May 6, 2026 4:04 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E May 6, 2026 4:03 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Inrig Jula May 6, 2026 4:03 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Dube Eric M May 6, 2026 9:55 AM - SEC Filing Form 144 Travere Therapeutics, Filed by: ROTE WILLIAM E. May 6, 2026 9:37 AM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $50 at Wells Fargo May 6, 2026 8:44 AM - StreetInsider Form 144 Travere Therapeutics, Filed by: Cline Christopher R. May 5, 2026 7:48 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E May 5, 2026 7:32 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Inrig Jula May 5, 2026 7:32 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Heerma Peter May 5, 2026 7:32 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Baynes Roy D. May 5, 2026 4:53 PM - SEC Filing Form 424B5 Travere Therapeutics, May 5, 2026 4:05 PM - SEC Filing Travere plans $400 million convertible notes offering to refinance debt May 5, 2026 4:01 PM - StreetInsider Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes May 5, 2026 4:01 PM - BizWire Travere Therapeutics (TVTX) PT Raised to $60 at TD Cowen May 5, 2026 8:54 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $54 at Jefferies May 5, 2026 7:42 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $57 at H.C. Wainwright May 5, 2026 7:34 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $59 at Citi May 5, 2026 4:03 AM - StreetInsider Form 10-Q Travere Therapeutics, For: Mar 31 May 4, 2026 4:46 PM - SEC Filing Form 4 Travere Therapeutics, For: May 01 Filed by: Baynes Roy D. May 4, 2026 4:27 PM - SEC Filing Form 8-K Travere Therapeutics, For: May 04 May 4, 2026 4:06 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E May 4, 2026 4:05 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Meckler Jeffrey A May 4, 2026 4:04 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Inrig Jula May 4, 2026 4:04 PM - SEC Filing Travere Therapeutics (TVTX) Misses Q1 EPS by 17c May 4, 2026 4:02 PM - StreetInsider Travere Therapeutics Reports First Quarter 2026 Financial Results May 4, 2026 4:01 PM - BizWire Form 144 Travere Therapeutics, Filed by: Baynes Roy D. May 1, 2026 4:16 PM - SEC Filing Form SCHEDULE 13G Travere Therapeutics, Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 30, 2026 2:08 PM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $50 at BofA Securities April 30, 2026 9:10 AM - StreetInsider Travere Therapeutics to Report First Quarter 2026 Financial Results April 27, 2026 4:30 PM - BizWire Travere Therapeutics (TVTX) PT Raised to $50 at Jefferies April 24, 2026 8:00 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $56 at Guggenheim April 24, 2026 6:40 AM - StreetInsider Full Article List